These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 2579718)
1. Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach. Battifora H; Kopinski MI Cancer; 1985 Apr; 55(8):1679-85. PubMed ID: 2579718 [TBL] [Abstract][Full Text] [Related]
2. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. Sheibani K; Battifora H; Burke JS Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942 [TBL] [Abstract][Full Text] [Related]
3. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Wirth PR; Legier J; Wright GL Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Holden J; Churg A Am J Surg Pathol; 1984 Apr; 8(4):277-9. PubMed ID: 6201076 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases. Otis CN; Carter D; Cole S; Battifora H Am J Surg Pathol; 1987 Jun; 11(6):445-56. PubMed ID: 2438954 [TBL] [Abstract][Full Text] [Related]
7. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Cibas ES; Corson JM; Pinkus GS Hum Pathol; 1987 Jan; 18(1):67-74. PubMed ID: 2434407 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies. Noguchi M; Nakajima T; Hirohashi S; Akiba T; Shimosato Y Hum Pathol; 1989 Jan; 20(1):53-7. PubMed ID: 2912874 [TBL] [Abstract][Full Text] [Related]
9. Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung. Tron V; Wright JL; Churg A Arch Pathol Lab Med; 1987 Mar; 111(3):291-3. PubMed ID: 2435259 [TBL] [Abstract][Full Text] [Related]
10. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies. Tuttle SE; Lucas JG; Bucci DM; Schlom J; Primus J J Surg Oncol; 1990 Oct; 45(2):72-8. PubMed ID: 2214794 [TBL] [Abstract][Full Text] [Related]
11. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects]. Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062 [TBL] [Abstract][Full Text] [Related]
12. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12. Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin. Duggan MA; Masters CB; Alexander F Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718 [TBL] [Abstract][Full Text] [Related]
14. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
15. The use of vimentin antibodies in the diagnosis of malignant mesothelioma. Jasani B; Edwards RE; Thomas ND; Gibbs AR Virchows Arch A Pathol Anat Histopathol; 1985; 406(4):441-8. PubMed ID: 3925619 [TBL] [Abstract][Full Text] [Related]
16. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry in the diagnosis of malignant mesothelioma. Pfaltz M; Odermatt B; Christen B; Rüttner JR Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887 [TBL] [Abstract][Full Text] [Related]
19. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions. al-Saffar N; Hasleton PS Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232 [TBL] [Abstract][Full Text] [Related]
20. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Corson JM; Pinkus GS Am J Pathol; 1982 Jul; 108(1):80-8. PubMed ID: 6178295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]